tetano
Editor, Senior Moderator
Bioorg Med Chem Lett
. 2024 Nov 21:130034.
doi: 10.1016/j.bmcl.2024.130034. Online ahead of print. Synthesis and Structure-Activity relationship of covalent inhibitors of SARS-CoV-2 papain-like protease with antiviral potency
Catherine C Rouch[SUP] 1 [/SUP], Arnab K Chatterjee[SUP] 1 [/SUP], Connor McCarty[SUP] 1 [/SUP], Lirui Song[SUP] 1 [/SUP], Alan Chu[SUP] 1 [/SUP], Kristen Johnson[SUP] 1 [/SUP], Mina Heacock[SUP] 1 [/SUP], Laura Riva[SUP] 1 [/SUP], Case W McNamara[SUP] 1 [/SUP], Karen C Wolff[SUP] 1 [/SUP], Rebecca Greene-Cramer[SUP] 2 [/SUP], Anna De Falco[SUP] 2 [/SUP], Gaetano T Montelione[SUP] 2 [/SUP], Gennadii A Grabovyi[SUP] 3 [/SUP]
Affiliations
The papain-like protease (PLpro) is a highly conserved domain encoded by the coronavirus (CoV) genome and it plays an essential role in the replication and maturation of the virus in addition to weakening host immune response. Due to the virus's reliance on PLpro for survival and propagation, small-molecule inhibitors of PLpro serve as an attractive model for direct-acting antiviral therapeutic agents against SARS-CoV-2. Building upon existing work aimed at designing covalent inhibitors against PLpro, we report the synthesis and structure-activity relationship of analogs based on the known covalent inhibitor 1 (Sanders, et al.2023). To evaluate the efficacy of synthesized derivatives, we conducted enzymatic inhibition assays, SARS-CoV-2/HeLa-ACE2 cellular potency and toxicity assays, and profiled the most promising analogs via in vitro ADME and in vivo pharmacokinetic studies. Additionally, we describe computational docking of profiled compounds bound to PLpro to elucidate the structure-activity relationship of compounds based on 1 and offer suggestions for optimizing the potency and selectivity of the electrophilic warhead and improving ADME and PK properties for this chemotype. Relative to the parent compound, new designs demonstrate comparable potency and target selectivity for PLpro. The accomplished SAR campaign provides novel insight for future development of antivirals against SARS-CoV-2.
Keywords: Antiviral; COVID-19; Covalent inhibitor; Fumarate ester; Papain-like protease; Pharmacokinetic; Structure–activity relationship.
. 2024 Nov 21:130034.
doi: 10.1016/j.bmcl.2024.130034. Online ahead of print. Synthesis and Structure-Activity relationship of covalent inhibitors of SARS-CoV-2 papain-like protease with antiviral potency
Catherine C Rouch[SUP] 1 [/SUP], Arnab K Chatterjee[SUP] 1 [/SUP], Connor McCarty[SUP] 1 [/SUP], Lirui Song[SUP] 1 [/SUP], Alan Chu[SUP] 1 [/SUP], Kristen Johnson[SUP] 1 [/SUP], Mina Heacock[SUP] 1 [/SUP], Laura Riva[SUP] 1 [/SUP], Case W McNamara[SUP] 1 [/SUP], Karen C Wolff[SUP] 1 [/SUP], Rebecca Greene-Cramer[SUP] 2 [/SUP], Anna De Falco[SUP] 2 [/SUP], Gaetano T Montelione[SUP] 2 [/SUP], Gennadii A Grabovyi[SUP] 3 [/SUP]
Affiliations
- PMID: 39580003
- DOI: 10.1016/j.bmcl.2024.130034
The papain-like protease (PLpro) is a highly conserved domain encoded by the coronavirus (CoV) genome and it plays an essential role in the replication and maturation of the virus in addition to weakening host immune response. Due to the virus's reliance on PLpro for survival and propagation, small-molecule inhibitors of PLpro serve as an attractive model for direct-acting antiviral therapeutic agents against SARS-CoV-2. Building upon existing work aimed at designing covalent inhibitors against PLpro, we report the synthesis and structure-activity relationship of analogs based on the known covalent inhibitor 1 (Sanders, et al.2023). To evaluate the efficacy of synthesized derivatives, we conducted enzymatic inhibition assays, SARS-CoV-2/HeLa-ACE2 cellular potency and toxicity assays, and profiled the most promising analogs via in vitro ADME and in vivo pharmacokinetic studies. Additionally, we describe computational docking of profiled compounds bound to PLpro to elucidate the structure-activity relationship of compounds based on 1 and offer suggestions for optimizing the potency and selectivity of the electrophilic warhead and improving ADME and PK properties for this chemotype. Relative to the parent compound, new designs demonstrate comparable potency and target selectivity for PLpro. The accomplished SAR campaign provides novel insight for future development of antivirals against SARS-CoV-2.
Keywords: Antiviral; COVID-19; Covalent inhibitor; Fumarate ester; Papain-like protease; Pharmacokinetic; Structure–activity relationship.